The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
27 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $24,952,403 in first-year total cost, median $947,652.
Most frequent study sections
- Special Emphasis Panel[ZCA1 GRB-I (M2)]18
- Special Emphasis Panel[ZCA1 GRB-S (M1)]9
Most frequent institutions
- DANA-FARBER CANCER INST4
- SLOAN-KETTERING INST CAN RESEARCH3
- COLUMBIA UNIVERSITY HEALTH SCIENCES2
- STANFORD UNIVERSITY2
- CASE WESTERN RESERVE UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | Targeting DNA Methylation and the Cancer Epigenome1R35CA209859-01 | JONES, PETER A | VAN ANDEL RESEARCH INSTITUTE, MI | $1,139,837 | ZCA1 |
| 2017 | Translating genomic discoveries to improved outcomes for high risk acute leukemia1R35CA197695-01A1 | MULLIGHAN, CHARLES G. | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN | $1,071,276 | ZCA1 |
| 2017 | Synergistic role of signaling and epigenetics in leukemic transformation1R35CA197594-01A1 | LEVINE, ROSS L | SLOAN-KETTERING INST CAN RESEARCH, NY | $1,028,400 | ZCA1 |
| 2017 | Isolation, characterization and translational development of glioma stem cells1R35CA210100-01 | PARADA, LUIS FERNANDO | SLOAN-KETTERING INST CAN RESEARCH, NY | $1,028,400 | ZCA1 |
| 2017 | Telomeres and Telomerase in Cancer1R35CA209974-01 | GREIDER, CAROL W | JOHNS HOPKINS UNIVERSITY, MD | $987,528 | ZCA1 |
| 2017 | Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment1R35CA197442-01A1 | MARKOWITZ, SANFORD D. | CASE WESTERN RESERVE UNIVERSITY, OH | $951,000 | ZCA1 |
| 2017 | Integrated approach to study early and late events in colonic neoplasia: mouse to man1R35CA197570-01A1 | COFFEY, ROBERT J. | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $947,652 | ZCA1 |
| 2017 | The Role of Stem Cells and the Microenvironment in Gastrointestinal Cancers1R35CA210088-01 | WANG, TIMOTHY CRAGIN | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $942,000 | ZCA1 |
| 2017 | Overcoming resistance to anti-PD1 immunotherapy1R35CA210098-01 | GAJEWSKI, THOMAS F | UNIVERSITY OF CHICAGO, IL | $941,158 | ZCA1 |
| 2017 | Human natural killer cells: Advancing biology and clinical applications1R35CA210087-01 | CALIGIURI, MICHAEL A | OHIO STATE UNIVERSITY, OH | $930,000 | ZCA1 |
| 2017 | Systems genetics analysis of tumor evolution in the mouse1R35CA210018-01 | BALMAIN, ALLAN | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $720,018 | ZCA1 |
| 2016 | Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer1R35CA210030-01 | STEGMAIER, KIMBERLY | DANA-FARBER CANCER INST, MA | $1,046,441 | ZCA1 |
| 2016 | Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer1R35CA210064-01 | LOOK, A. THOMAS | DANA-FARBER CANCER INST, MA | $1,046,441 | ZCA1 |
| 2016 | Studies on oncoprotein-induced feedback: Basic and therapeutic implications1R35CA210085-01 | ROSEN, NEAL | SLOAN-KETTERING INST CAN RESEARCH, NY | $1,028,400 | ZCA1 |
| 2016 | Phosphoinositides and Cancer Metabolism1R35CA197588-01A1 | CANTLEY, LEWIS C. | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $1,017,000 | ZCA1 |
| 2016 | Oncogenic Ras-induced macropinocytosis: A new paradigm for metabolic adaptation1R35CA210263-01 | BAR-SAGI, DAFNA | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $1,017,000 | ZCA1 |
| 2016 | Retrovirus Evolution and Cancer1R35CA200421-01A1 | COFFIN, JOHN M | TUFTS UNIVERSITY BOSTON, MA | $990,000 | ZCA1 |
| 2016 | New Paradigms for Targeting Truncal Driver Mutations1R35CA210068-01 | KAELIN, WILLIAM G. | DANA-FARBER CANCER INST, MA | $982,500 | ZCA1 |
| 2016 | Immunoprevention and immunosurveillance of human non-viral cancers1R35CA210039-01 | FINN, OLIVERA J | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $941,449 | ZCA1 |
| 2016 | Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host1R35CA197353-01A1 | LEVY, RONALD | STANFORD UNIVERSITY, CA | $924,071 | ZCA1 |
| 2016 | Genome instability in cancer: telomeres and DNA repair1R35CA210036-01 | DE LANGE, TITIA | ROCKEFELLER UNIVERSITY, NY | $902,733 | ZCA1 |
| 2016 | TET enzymes as guardians of genome stability1R35CA210043-01 | RAO, ANJANA | LA JOLLA INSTITUTE FOR IMMUNOLOGY, CA | $864,061 | ZCA1 |
| 2016 | Defining the functions and translational potential of ferroptosis1R35CA209896-01 | STOCKWELL, BRENT R. | COLUMBIA UNIV NEW YORK MORNINGSIDE, NY | $809,277 | ZCA1 |
| 2016 | Harnessing Host Response to Prevent Myeloma1R35CA197603-01A1 | DHODAPKAR, MADHAV V | YALE UNIVERSITY, CT | $789,240 | ZCA1 |
| 2016 | Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer1R35CA210057-01 | ZHAO, JEAN | DANA-FARBER CANCER INST, MA | $775,816 | ZCA1 |
| 2016 | LncRNA mechanisms in cancer1R35CA209919-01 | CHANG, HOWARD Y | STANFORD UNIVERSITY, CA | $724,705 | ZCA1 |
| 2016 | From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma1R35CA210105-01 | DALLA-FAVERA, RICCARDO | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $406,000 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.